Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04080804 · ClinicalTrials.gov registry record · Phase 2
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer
A Phase 2 study of Head and Neck Squamous Cell Carcinoma (HNSCC), sponsored by Dan Zandberg.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT04080804 is a Phase 2 study of Head and Neck Squamous Cell Carcinoma (HNSCC) that is actively recruiting participants, run by Dan Zandberg. The registered enrollment target is 80 participants, below the 257-participant average among 13 other Head and Neck Squamous Cell Carcinoma (HNSCC) trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04080804, a Phase 2 study of Head and Neck Squamous Cell Carcinoma (HNSCC), is actively recruiting participants, sponsored by Dan Zandberg.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to potentiate adaptive immunity to enhance the anti-tumor activity of anti-PD1 antibody by the addition of anti-CTLA4 antibody or anti-LAG3 antibody (relatlimab) given in subjects with resectable locally advanced HNSCC prior to surgical resection.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG Relatlimab
Study Locations (1)
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2019-12-20 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04080804
The ClinicalTrials.gov registry entry for NCT04080804 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 13 other Head and Neck Squamous Cell Carcinoma (HNSCC) trials with a reported enrollment target (69% lower). The listed sponsor is Dan Zandberg, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Head and Neck Squamous Cell Carcinoma (HNSCC) appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT04080804 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04080804 about?
NCT04080804 is a clinical study titled "Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer". The aim of this study is to potentiate adaptive immunity to enhance the anti-tumor activity of anti-PD1 antibody by the addition of anti-CTLA4 antibody or anti-LAG3 antibody (relatlimab) given in subjects with resectable locally advanced HNSCC prior to surgical resection.
What is the current status of trial NCT04080804?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2019-12-20. Estimated completion is 2026-10-31.
What conditions does trial NCT04080804 study?
This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma (HNSCC).
What interventions are being tested in trial NCT04080804?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Relatlimab (DRUG).
Who is sponsoring clinical trial NCT04080804?
This trial is sponsored by Dan Zandberg, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04080804 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Squamous Cell Carcinoma (HNSCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RECRUITING · Phase 2
-
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
RECRUITING · Phase 2
-
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
-
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.